Search
Research
Pandemic influenza H1N1 2009 infection in Victoria, AustraliaConflicting findings regarding the level of protection offered by seasonal influenza vaccination against pandemic influenza H1N1 have been reported.
Research
Crowding and other strong predictors of upper respiratory tract carriage of otitis media-relatedWe investigated predictors of nasopharyngeal carriage in Australian Aboriginal and non-Aboriginal children.
Research
Immunogenicity and safety of a combined Haemophilus influenzae type b-NeisseriaNeisseria meningitidis serogroups B, C, and Y cause most meningococcal disease in industrialized countries...
Research
Safety and Immunogencity of a Prototype Adjuvanted Inactivated Split-Virus Influenza A (H5N1) Vaccine in Infants and ChildrenHighly pathogenic avian influenza A virus (H5N1) is a leading candidate for the next influenza pandemic, and infants and children may play an important role...
Research
Mapping Bacillus Calmette-Guérin vaccination coverage in Africa from 1990 to 2022: a novel spatiotemporal modelling studyBacillus Calmette-Guérin (BCG) protects children from severe tuberculosis and remains the only licensed vaccine for tuberculosis. Subnational estimates of BCG coverage are essential for identifying underserved populations across Africa. This study aimed to map BCG vaccination coverage in Africa from 1990 to 2022.
Research
Prevention of rheumatic heart disease in New Zealand: High-dose subcutaneous benzathine penicillin is cost-saving compared with traditional intramuscular injectionsAcute rheumatic fever is a preventable condition that can lead to chronic illness and early death. Standard prevention with 4-weekly intramuscular (IM) benzathine penicillin G (BPG) injections for ≥10 years may be associated with poor adherence. High-dose 10-weekly subcutaneous penicillin injections (SCIP) may improve adherence by reducing injection frequency.
Research
Boosting the influenza vaccine schedule in children with cancer: a prospective open-label studyCurrent immunization guidelines recommend one dose of influenza vaccine for children aged ≥9 years and two doses for younger or vaccine-naïve children. However, children receiving chemotherapy have an attenuated immune response. We performed a prospective open-label study in children undergoing treatment for cancer at Perth Children's Hospital, Western Australia, to examine the safety and efficacy of a boosted influenza schedule.
Research
Immunogenicity and Safety of a 2 + 1 DTPa Priming Schedule in Australian Infants and the Impact of Maternally Derived Antibodies on Pertussis Antibody Responses up to 4 Years of AgeWe assessed the impact of maternally derived pertussis antibodies on infant responses to a 2 + 1 vaccine schedule (6 weeks, 12 weeks, and 12 months). Infants with baseline antibodies showed lower IgG responses following the primary vaccination series, but this did not impair booster responses at 4 years of age.
Latest news & events at the Wesfarmers Centre of Vaccines & Infectious Diseases.
Research
Severe adverse reactions to benzathine penicillin G in rheumatic heart disease: A systematic review and meta-analysisFear of severe adverse reaction (SAR) and reluctance of health care providers to administer intramuscular injections are major contributing factors to poor adherence of benzathine penicillin G (BPG) in the management of rheumatic heart disease (RHD). However, data on the risk of SARs following BPG injections for RHD are relatively limited and inconclusive. Our systematic review and meta-analysis aimed to evaluate the incidence of SARs associated with BPG injections used for secondary prophylaxis of RHD.